GRI Bio, Inc. Common Stock
Compare this stock
GRI Stock Report Card
$
21%
Performance
Score:
10/100
GRI returned -91.59% in the last 12 months. Based on SPY's performance of 15.17%, its performance is below average giving it a score of 10 of 100.
Profit
Score:
20/100
Out of the last 4 quarters, GRI has had 1 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
36/100
GRI has had a lower than average amount of volatility over the last 12 months giving it a score of 36 of 100.
GRI Bio, Inc. Common Stock Summary
Nasdaq / GRI
Healthcare
Biotechnology
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
GRI scored poorly on our reportcard. Here are some similar companies and how they performed.
